2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Omics Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Immunology, Neutropenia, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

5610 Trial in progress: Bexera, a randomized, double-blind, placebo-controlled Phase 2b study of bexmarilimab plus azacitidine in treatment-naïve higher-risk myelodysplastic syndromes

Amer M. Zeidan, MD, Austin G. Kulasekararaj, MD, MBBS, FRCPath, MRCP2, Christophe Willekens, MD3, Antonio Curti Sr, MD4, Anthony Selwyn Stein, MD5, Naval Daver, MD6, Vladimir Otasevic, MD, PhD7, Joab Williamson, MBA, PhD8, Petri Bono, MD, PhD9, Aneel Nimba10, Sofia Aakko, PhD11, Guillermo Garcia-Manero, MD12, Mika Kontro, MD, PhD13
1 Yale University School of Medicine and Yale Comprehensive Cancer Center, New Haven, United States
2 King's College Hospital, London, United Kingdom
3 Institute Gustave Roussy, Villejuif, France
4 University of Bologna, Bologna, Italy
5 City of Hope, Duarte, California, United States
6 MD Anderson Cancer Center, Houston, Texas, United States
7 Parexel, Siena, Italy
8 Faron Pharmaceuticals Ltd, Turku, Finland
9 Faron Pharmaceuticals Ltd, Turku, Finland
10 Faron Pharmaceuticals Ltd, Turku, Finland
11 Faron Pharmaceuticals Ltd, Turku, Finland
12 MD Anderson Cancer Center, Houston, Texas, United States
13 HUS Comprehensive Cancer Center, Helsinki, Finland

Background: Higher-risk myelodysplastic syndromes (HR-MDS) remain associated with poor outcomes despite frontline hypomethylating agent therapy, and randomized data are needed before advancing new azacitidine-based combinations into pivotal development. Bexmarilimab is a first-in-class humanized IgG4 monoclonal antibody targeting Clever-1/Stabilin-1, an immunosuppressive macrophage and myeloid cell scavenger receptor. Inhibition of Clever-1 is intended to reprogram macrophages toward immune activation and may complement the immunomodulatory effects of azacitidine. In previously reported BEXMAB findings in frontline HR-MDS, bexmarilimab plus azacitidine demonstrated encouraging remission and MRD-negativity signals, including 45% CR under IWG 2006, 41% CR/CReq under IWG 2023, and 45% MRD negativity. BEXERA is designed to select the recommended dose of bexmarilimab plus azacitidine for subsequent registrational development and is, to our knowledge, the first randomized HR-MDS trial to prospectively combine IPSS-M-defined eligibility/stratification with IWG 2023 response assessment.

Methods: BEXERA (FP2CLI012; EU CT: 2026-526706-33-00; ClinicalTrials.gov: NCT07672769) is a multicenter, multinational, randomized, double-blind, placebo-controlled, parallel-group phase 2b trial in treatment-naïve HR-MDS. Approximately 90 adults will be enrolled at approximately 35 sites in North America and Europe and randomized 1:1:1 to bexmarilimab 1 mg/kg, bexmarilimab 3 mg/kg, or placebo, each administered intravenously once weekly in cycles 1-3 and combined with the participant’s routine regimen of azacitidine per local label/institutional practice. After cycle 3, participants with complete remission (CR) or CR equivalent (CReq) may switch to every-2-week bexmarilimab/placebo dosing at investigator discretion. Treatment may continue for up to 36 months or until disease progression, loss of clinical benefit, unacceptable toxicity, initiation of new antineoplastic therapy, allogeneic hematopoietic stem cell transplantation (allo-HSCT), withdrawal, or trial termination.

Eligible participants are aged >=18 years with newly diagnosed, morphologically confirmed HR-MDS according to WHO 2022 criteria, IPSS-M moderate-high/high/very-high risk, <20% bone marrow blasts, ECOG performance status 0-2, adequate organ function, and eligibility for azacitidine. Key exclusions include prior disease-modifying therapy for MDS, prior or transformed acute myeloid leukemia, MDS/myeloproliferative neoplasm overlap syndromes, immediate candidacy for allo-HSCT, uncontrolled infection, and active autoimmune disease requiring systemic therapy. Participants with <5% baseline bone marrow blasts must have cytogenetic abnormalities; this subgroup is capped at 25% of total enrollment.

Randomization is stratified by IPSS-M risk category, baseline bone marrow blasts (<5% vs >=5%), and TP53 mutation status. The primary dose-selection analysis will occur after all enrolled participants have at least 3 months of follow-up from treatment start. Dose selection will use a prospectively defined risk-benefit utility score integrating efficacy, defined as best CR or CReq per IWG 2023 before database lock, and safety/tolerability, defined by protocol-specified grade 3-5 treatment-related adverse events. An independent data monitoring committee will review unblinded data, including supportive pharmacokinetic, pharmacodynamic, immunogenicity, and efficacy information, before recommending the dose for subsequent development. Key secondary and supportive endpoints include CR+CReq rate, IWG 2023 composite CR and overall response rate, IWG 2006 CR and overall response rate, overall survival, event-free survival, duration and time to response, transformation to AML, allo-HSCT rate, infections and hospitalizations, transfusion independence, minimal residual disease, serum bexmarilimab exposure, anti-drug antibodies, soluble Clever-1, bone marrow biomarkers, and subgroup analyses based on prespecified stratification factors.

Amer M. Zeidan, MD: AbbVie, Akesobio, Agios, Amgen, Astellas, BioCryst, BioThera, BeiOne, Boehringer Ingelheim, Celgene/BMS, Chiesi/Cornerstone, Daiichi-Sankyo, Dr.Reddy’s, Epizyme, Faron, Fibrogen, GSK, Glycomimetics, Genentech, Gilead, Geron, Innocare, Janssen, Jasper, Karyopharm, Kyowa Kirin, Keros, Kura, Novartis, Notable, Oncoverity, Orum, Otsuka, Pfizer, Puretech/Gallop Technology, Regeneron, Rigel, Seattle Genetics, Shattuck Labs, Schrodinger, Sumitomo, Syros, Syndax, Systimmune, Sillajen, Servier, Takeda, Treadwell, Taiho, Vincerx, and Zentalis - Consultancy (Includes expert testimony); AbbVie, Akesobio, Agios, Amgen, Astellas, BioCryst, BioThera, BeiOne, Boehringer Ingelheim, Celgene/BMS, Chiesi/Cornerstone, Daiichi-Sankyo, Dr.Reddy’s, Epizyme, Faron, Fibrogen, GSK, Glycomimetics, Genentech, Gilead, Geron, Innocare, Janssen, Jasper, Karyopharm, Kyowa Kirin, Keros, Kura, Novartis, Notable, Oncoverity, Orum, Otsuka, Pfizer, Puretech/Gallop Technology, Regeneron, Rigel, Seattle Genetics, Shattuck Labs, Schrodinger, Sumitomo, Syros, Syndax, Systimmune, Sillajen, Servier, Takeda, Treadwell, Taiho, Vincerx, and Zentalis - Consultancy (Includes expert testimony)